Daniel B. Tumas

Supplementary Data from Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219

Cheng‐Yu Tsai, Adrian S. Ray, Daniel B. Tumas, Michael J. Keating et autres

Supplementary Data from Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219

Data from Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219

Cheng‐Yu Tsai, Adrian S. Ray, Daniel B. Tumas, Michael J. Keating et autres

Abstract Purpose: GS-9219 is a cell-permeable prodrug of the acyclic nucleotide analogue 9-(2-phosphonylmethoxyethyl)guanine (PMEG); the incorporation of the active metabolite PMEG diphosphate (PMEGpp) into DNA results in DNA chain termination due to the lack of a 3′-hydroxyl moiety. We hypothesized that the …

Data from Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219

Cheng‐Yu Tsai, Adrian S. Ray, Daniel B. Tumas, Michael J. Keating et autres

Abstract Purpose: GS-9219 is a cell-permeable prodrug of the acyclic nucleotide analogue 9-(2-phosphonylmethoxyethyl)guanine (PMEG); the incorporation of the active metabolite PMEG diphosphate (PMEGpp) into DNA results in DNA chain termination due to the lack of a 3′-hydroxyl moiety. We hypothesized that the …

Supplementary Data from Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219

Cheng‐Yu Tsai, Adrian S. Ray, Daniel B. Tumas, Michael J. Keating et autres

Supplementary Data from Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219

Delirium is one of the many faces of COVID-19. Literature review

A. Bagdonaitė, Daniel B. Tumas, Eglė Griškevičiūtė, A. Svirskytė

Taking into account today’s context of COVID-19 disease, it is very important to acknowledge the serious psychiatric complications that arise during the acute phase of the disease, as well as those that have a delayed onset and are no less dangerous. COVID-19 …

lt (code pays fourni par la source)

The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH

Philipp Schwabl, Grant R. Budas, Eva Hambruch, Paul Supper et autres

A liver-targeted acetyl CoA carboxylase inhibitor reduces hepatic steatosis and liver injury in a murine model of NASH

Jamie Bates, Robert Brockett, I. Mikaelian, Tony Chang Wang et autres

Combination of an ASK1 inhibitor and FXR agonist increases efficacy in a mouse model of non-alcoholic steatohepatitis

J.T. Liles, Anna Zagórska, David Hollenback, Grant R. Budas et autres

POLYTHÉRAPIE POUR TRAITER DES TUMEURS À CELLULES B

Helen Collins, Julie Di Paolo, Kathy Keegan, Ryohei Kozaki et autres

The Combination of a BET Inhibitor (GS-5829) and a BTK Inhibitor (GS-4059) Potentiates DLBCL Cell Line Cell Death and Reduces Expression of MYC, IL-10, and IL-6 in Vitro

Jamie Bates, Saritha Kusam, Stacey L. Tannheimer, Julie Chan et autres

Abstract Introduction: GS-5829 is a potent and selective inhibitor of thebromodomain and extra-terminal (BET) family of proteins. BET proteins regulate the transcription of key oncogenes including MYC resulting in cancer cell growth (Yang Z. et. al.Mol CellBiol 2008; LeRoy G. et al.Mol …

us (code pays fourni par la source)

Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines

Jamie Bates, Saritha Kusam, Stacey L. Tannheimer, Astrid S. Clarke et autres

Abstract Introduction: GS-5829 is a potent and selective inhibitor of the bromodomain and extra-terminal (BET) family of proteins. BET proteins regulate the transcription of key oncogenes including MYC, resulting in cancer cell growth (Yang Z. et. al. Mol Cell Biol 2008; LeRoy …

us (code pays fourni par la source)

Fxr Agonism by Gs-9674 Decreases Steatosis and Fibrosis in a Murine Model of Nash

J.T. Liles, Satyajit K. Karnik, Eva Hambruch, Claus Kremoser et autres